Pred-G® Ointment
gentamicin 0.3% / prednisolone acetate 0.6% · ophthalmic ointment
Antibiotic/Steroid
Approved uses
Steroid-responsive ocular inflammation with superficial bacterial infection or a risk of it, including chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or foreign body penetration
1/2 inch ribbon in the conjunctival sac 1 to 3 times daily; not more than 8 g initially
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
- Known or suspected hypersensitivity to any ingredient of the preparation or to other corticosteroids
Gentamicin 0.3% and prednisolone acetate 0.6% ointment, 3.5 g tube
Corticosteroids suppress the inflammatory response to many agents and probably delay or slow healing. Because they may inhibit the body's defense mechanism against infection, a concomitant antimicrobial may be used when this inhibition is considered clinically significant in a particular case. The gentamicin sulfate component is active in vitro against susceptible strains of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. A review of annexin 1 reports that glucocorticoids may induce it in inflammatory cells and that it may target cytosolic phospholipase A2 by direct enzyme inhibition. A microbiology text states that aminoglycosides bind the 30S subunit, which blocks the initiation complex.
Warnings & Precautions
- Elevated IOP: Prolonged corticosteroid use may result in glaucoma with optic nerve damage and defects in visual acuity and fields of vision; monitor IOP routinely when used 10 days or longer, and use with caution in the presence of glaucoma.
- Posterior subcapsular cataract: Prolonged corticosteroid use may produce cataract formation.
- Secondary ocular infection: Prolonged use of corticosteroids may suppress the host immune response and increase the hazard of secondary ocular infections; acute purulent infections of the eye may be masked or enhanced by the corticosteroid, and secondary ocular infection has occurred after use of combinations containing steroids and antimicrobials.
- Ocular irritation and punctate keratitis: Ocular irritation and punctate keratitis have been associated with the use of this ointment.
- Corneal and scleral thinning: Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning, and use in the presence of thin corneal or scleral tissue may lead to perforation.
- Fungal invasion: Suspect fungal infection in any persistent corneal ulceration where a corticosteroid has been used or is in use, and take fungal cultures when appropriate.
- Viral eye infections: Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex); in patients with a history of herpes simplex, a corticosteroid requires great caution, and frequent slit lamp microscopy is recommended.
- Delayed healing after cataract surgery: Steroid use may delay healing and increase the incidence of bleb formation.
- Renewal examination: The initial prescription and renewal beyond 8 grams should be made only after examination of the patient's intraocular pressure and examination with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
- Corneal epithelial toxicity: In rabbits, gentamicin sulfate was among the most toxic of eight topical antibiotic solutions tested on corneal epithelial wound healing, though that study tested solutions and did not test an ointment vehicle.
Common Side Effects
The most frequent reactions are ocular discomfort, irritation upon instillation and punctate keratitis, which have resolved upon discontinuation; exact incidence figures are not available. Other reported reactions include eye burning, eye stinging, ocular hyperemia, eye pain, eye discharge, increased lacrimation, eye edema, visual impairment, blurry vision, foreign body sensation and dysgeusia. Hypersensitivity has also been reported, including ocular allergy, angioedema and allergic skin reactions. Allergic sensitization is the reaction occurring most often from the anti-infective ingredient. Reactions due to the steroid component, in decreasing order of frequency, are elevation of IOP with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing.
Pregnancy: Systemic gentamicin in pregnant rats at approximately 500 times the maximum recommended ophthalmic human dose depressed newborn body weights, kidney weights and median glomerular counts, and prednisolone is teratogenic in mice at 1 to 10 times the human ocular dose; when dexamethasone, hydrocortisone and prednisolone were applied to both eyes of pregnant mice five times per day on gestation days 10 through 13, a significant increase in the incidence of cleft palate was observed in the fetuses. No adequate well-controlled studies in pregnant women, so use only if the potential benefit justifies the potential risk to the fetus.
Lactation: Unknown whether topical administration produces detectable quantities in breast milk; systemically administered corticosteroids do appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause untoward effects. Because of the potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or to discontinue the medication.
Safety and effectiveness in pediatric patients have not been established.